Drug Discovery Today
AUGUST 31, 2022
In the lead up to the inaugural launch of Connect In Pharma, co-founder Wilfried Phipps provides insight into what visitors can expect at this new annual event designed to help shape the future of pharmaceutical packaging and manufacturing projects
Antidote
AUGUST 29, 2022
In the world of medical research, experts are constantly looking for new drugs, treatments, and therapies for a variety of conditions — but the process of getting these treatments approved is only possible if they are tested through clinical trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for ARISTADA Aristada is a drug marketed by Alkermes Inc and is included in two NDAs. It is available from one supplier. There are sixteen patents…. The post New patent for Alkermes Inc drug ARISTADA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
AUGUST 15, 2022
Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! Even better, my Freedom of Information Act (FOIA) request was able to pry out detailed purchases by covered entity type. The data tell a familiar story. For 2021, discounted purchases under the 340B program reached a record $43.9 billion —an astonishing $5.9 billion (+15.6%) higher than its 2020 counterpart.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Policy Prescription
AUGUST 25, 2022
This past June, during a debate in the Senate Health, Education, Labor and Pensions (HELP) Committee, Senator Richard Burr (R-NC), the committee’s Ranking Member, demonstrated that he does not understand very important developments in our nation’s approach to drug regulation and safety. It was almost as if Sen. Burr had fallen asleep over 20 years ago and woke up believing that nothing had changed in the world of drug regulation.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Discovery Today
AUGUST 24, 2022
Togo receives an outstanding achievement award as the first ever country to eliminate four neglected tropical diseases (NTDs) at the 72nd session of the WHO Regional Committee for Africa
Antidote
AUGUST 17, 2022
Clinical research studies around the United States are in need of participants to learn more about various conditions. For those interested in learning how to take part in research, finding clinical trials that might be a fit can be simple — by answering a few questions about your location and medical history, you can see all the active trials you may be eligible for.
Drug Patent Watch
AUGUST 18, 2022
This chart shows the pharmaceutical companies with the most patents in Norway. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Norway? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
AUGUST 26, 2022
Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx. Chris discusses the benefits of using in-electronic health record (EHR) messaging to communicate formulary information to both healthcare providers and patients during the patient encounter. Click here to learn more about ConnectiveRx’s in-EHR messaging.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Advarra
AUGUST 31, 2022
In response to a growing demand for faster, approved, and cost-effective medical devices for chronic diseases, medical device manufacturers and emerging biotech companies are facing increasingly complex pathways to successfully bring their innovative ideas to the market. If a new medical device, software as a medical device (SaMD), or in vitro diagnostic (IVD) is poised to successfully make it through the development process to commercialization, sponsors must consider a trifecta of interconnect
Eye on FDA
AUGUST 17, 2022
Periodically I write a posting to look back at what FDA is talking about to get some perspective. Each individual press release tells us something, but looking back at the aggregate can also provide insights. Not long ago, a retrospective look that compared the ratio and trend of COVID versus non-COVID related news out of FDA suggested that not only was COVID becoming less of a topic for the agency, but also presented the possibility that there was increasing room for other topics.
Drug Discovery Today
AUGUST 15, 2022
The topic of this month’s newsletter from Drug Discovery Today is “Medicinal Chemistry”.
Antidote
AUGUST 22, 2022
Online communities have long provided people with the opportunity to connect with others across the globe, and as the internet has become more ubiquitous in our day-to-day lives, their popularity has only increased. Online groups often pop up surrounding a variety of focuses, from gardening to antiquing to listening to a particular podcast — but they have also become an important way for patients to connect with one another.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
AUGUST 20, 2022
This chart shows the pharmaceutical companies with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
AUGUST 9, 2022
Over the weekend, the U.S. Senate passed a massive overhaul of the Medicare Part D program. If passed into law, these changes will have many unintended consequences , but will not address the warped incentives baked into our current rebate system. This makes it a good time to review the murky, little-seen economics of how commercial plan sponsors and payers access the billions of dollars in manufacturer rebates and fee that are negotiated by their pharmacy benefit managers (PBMs).
Advarra
AUGUST 31, 2022
Institutional biosafety committees (IBCs) frequently receive questions about the proper methodology for preparing a syringe for transport from a drug room or pharmacy to the clinic where the injection will be administered. This article explores tools and techniques to safely mitigate occupational exposure risks when preparing a syringe for transport to the clinic.
Crown Bioscience
AUGUST 25, 2022
Targeted therapies have altered the landscape of cancer treatment across an increasing number of cancer types. While these drugs have significantly benefited many cancer patients, a major ongoing challenge associated with targeted therapies is acquired drug resistance, which is believed to be a key factor in cancer-related deaths. In this post we explore how acquired drug resistance to targeted therapies can be tackled by using in vivo patient-derived xenograft (PDX) models, which are effective
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Discovery Today
AUGUST 18, 2022
Reading, 12 August 2022. Sanofi (EURONEXT: SAN and NASDAQ: SNY) and the National Institute for Health and Care Research (NIHR) have today announced that the first patient has been enrolled in the Hospitalised RSV Monoclonal Antibody Prevention (HARMONIE) study. The large European interventional clinical study is investigating protection against Respiratory syncytial virus (RSV) in infants.
Antidote
AUGUST 19, 2022
Celiac disease, an autoimmune disorder that causes a reaction to gluten, is a condition that impacts about 1 in 141 people in the United States. For those with celiac disease, ingesting gluten creates toxins that destroy the villi of the small intestine, which makes it difficult for the body to absorb nutrients from food.
Drug Patent Watch
AUGUST 10, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Austria. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Austria? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
AUGUST 19, 2022
Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds. John discusses how a patient-centric technology solution can increase access and affordability for patients. He goes on to describe how human contact and support helps patients understand their disease and their treatment plan, thus increasing adherence.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Broad Institute
AUGUST 24, 2022
Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer By Tom Ulrich August 24, 2022 Breadcrumb Home News Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer Integrated approach highlights potential therapeutic opportunities for a challenging tumor type By Molly Chiu, Baylor College of Medicine August 24, 2022 NCI )" title="Triple-negative breast cancer cells (blue).
ProRelix Research
AUGUST 23, 2022
Real-World Evidence Studies: Introduction, Purpose, and Data Collection Strategy The first image that comes to mind when one thinks of where safety and efficacy data for a new treatment is […]. The post Real-World Evidence Studies: Introduction, Purpose, and Data Collection Strategy appeared first on ProRelix Research.
Drug Discovery Today
AUGUST 9, 2022
The newly announced agenda for Connect in Pharma focuses on innovation as the foundation of a strong pharmaceutical industry in Europe
Antidote
AUGUST 8, 2022
Medical research is how new treatments and therapies move forward, but challenges surrounding patient recruitment can often lead to delays. Patients often have misconceptions about participating in a clinical trial — and if they are interested, they often aren’t sure where to begin.
Drug Patent Watch
AUGUST 15, 2022
Annual Drug Patent Expirations for IMBRUVICA Imbruvica is a drug marketed by Pharmacyclics Inc and is included in two NDAs. It is available from one supplier. There are forty patents…. The post New patent for Pharmacyclics Inc drug IMBRUVICA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
113 
Let's personalize your content